Simbrinza
Payments companies reported to CMS as associated with Simbrinza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Simbrinza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Simbrinza
These are the largest totals companies reported as associated with Simbrinza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amy Miller | Dayton, OH | Ophthalmology | $43,366.76 |
| Joseph Panarelli | New York, NY | Ophthalmology | $34,568.69 |
| Jason Bacharach | Petaluma, CA | Glaucoma Specialist | $32,129.25 |
| Constance Okeke | Norfolk, VA | Ophthalmology | $32,042.65 |
| Gregory Katz | Ypsilanti, MI | Ophthalmology | $26,619.02 |
| Oluwatosin Smith | Dallas, TX | Ophthalmology | $26,476.75 |
| Analisa Arosemena | Miami Beach, FL | Glaucoma Specialist | $22,968.78 |
| Gagan Sawhney | Atlanta, GA | Ophthalmology | $22,448.67 |
| Bac Nguyen | Houston, TX | Ophthalmology | $20,283.28 |
| Sean Smolenyak | Raleigh, NC | Optometrist | $19,887.64 |
Prescribed Simbrinza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.